1. Home
  2. AYTU vs STRR Comparison

AYTU vs STRR Comparison

Compare AYTU & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • STRR
  • Stock Information
  • Founded
  • AYTU N/A
  • STRR 1985
  • Country
  • AYTU United States
  • STRR United States
  • Employees
  • AYTU N/A
  • STRR N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • AYTU Health Care
  • STRR Health Care
  • Exchange
  • AYTU Nasdaq
  • STRR Nasdaq
  • Market Cap
  • AYTU 15.0M
  • STRR 13.3M
  • IPO Year
  • AYTU N/A
  • STRR N/A
  • Fundamental
  • Price
  • AYTU $2.24
  • STRR $3.90
  • Analyst Decision
  • AYTU
  • STRR
  • Analyst Count
  • AYTU 0
  • STRR 0
  • Target Price
  • AYTU N/A
  • STRR N/A
  • AVG Volume (30 Days)
  • AYTU 31.6K
  • STRR 8.9K
  • Earning Date
  • AYTU 11-12-2024
  • STRR 11-06-2024
  • Dividend Yield
  • AYTU N/A
  • STRR N/A
  • EPS Growth
  • AYTU N/A
  • STRR N/A
  • EPS
  • AYTU N/A
  • STRR N/A
  • Revenue
  • AYTU $81,002,000.00
  • STRR $47,147,000.00
  • Revenue This Year
  • AYTU N/A
  • STRR $19.97
  • Revenue Next Year
  • AYTU N/A
  • STRR $41.50
  • P/E Ratio
  • AYTU N/A
  • STRR N/A
  • Revenue Growth
  • AYTU N/A
  • STRR N/A
  • 52 Week Low
  • AYTU $2.11
  • STRR $3.43
  • 52 Week High
  • AYTU $3.50
  • STRR $6.55
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 40.89
  • STRR 41.38
  • Support Level
  • AYTU $2.11
  • STRR $3.89
  • Resistance Level
  • AYTU $2.44
  • STRR $4.29
  • Average True Range (ATR)
  • AYTU 0.14
  • STRR 0.22
  • MACD
  • AYTU -0.02
  • STRR -0.02
  • Stochastic Oscillator
  • AYTU 17.57
  • STRR 10.96

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complimentary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. AR101/enzastaurin has received Orphan Drug designation from the FDA. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which it generates maximum revenue from the Rx segment.

About STRR Star Equity Holdings Inc.

Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.

Share on Social Networks: